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signiﬁcantly more likely to experience an ER visit or an inpatient stay compared to 
patients in capitated plans (odds ratio for ER visit: 1.64, p < 0.05; odds ratio for an 
inpatient stay: 1.11, p < 0.05). CONCLUSIONS: The results of this study conﬁrm 
that utilization rates are higher in FFS plans; however, the strength of the association 
was not as robust when the regression models were adjusted for propensity score. 
Capitated plans seek to reduce resource utilization.
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COMPARATIVE RESULTS ON EFFECTS OF TYPES OF INSURANCE AND 
PAYMENT PLANS ON PHYSICIANS’COST AWARENESS DURING THE 
PHYSICIAN VISIT USING THE NAMCS SURVEY IN 1996 AND 2005
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OBJECTIVES: This paper compares physician’s cost awareness of types of payments 
and insurance status at the point of visit, using two analytical datasets extracted from 
the National Ambulatory Medical Care survey (NAMCS) on patients diagnosed with 
Type II diabetes without complications. It analyzes the effects of various changes in 
the physician survey. METHODS: Two analytical datasets are constructed for diabetic 
patients Type II with no complication identiﬁed with code 25.00, one of 694 individu-
als in 1996 and one of 620 for 2005. Pharmacological treatment has been deﬁned by 
building two drug lists for 1995/1996/1997 and 2004–2005–2006 from Facts and 
Comparisons books (one year before - one year after the year of reference) and the 
Brixner et als study (2008). Drug codes used for the two periods are generic codes. 
The coding has been revised in order to integrate the withdrawal of FDA codes and 
the transition to new Multum drug classiﬁcation system. A disease economic model 
is used. Dependent variables represent access and use of drug therapy. RESULTS: 
Drug codes for the two references periods substantially differ. New development of 
the disease model are described between 1996 and 2005 to integrate these drug codes 
changes,the introduction of electronic records, new types of ﬁnancial information, new 
beneﬁt designs and changes of clinical guidelines. It transforms the previous series of 
cross sectional modeling tested on 3 chronic conditions into a time series and dynamic 
framework. The model describes prescribing patterns of new versus old classes (espe-
cially TZD and new insulin analogs), evolution of modes of administration and impact 
of electronic records. CONCLUSIONS: The paper contributes to show the interest of 
disease modeling not only by medical schools but also with an economic perspective. 
Even after triages from health care administrators for categorization of patients into 
various health plans, physicians are cost aware at the time of visit and this inﬂuences 
their prescribing decisions.
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USING DECISION MODELING TO DETERMINE COST-EFFECTIVENESS 
OF PHARMACIST INTERVENTIONS FOR PATIENTS WITH DIABETES
Pinto S, Holl S
University of Toledo, Toledo, OH, USA
OBJECTIVES: Prevention or mediation of adverse events can signiﬁcantly impact a 
patient’s quality of life and their employer’s health care costs. Decision modeling can 
be utilized to map pharmacists interventions provided through an employee-sponsored 
medication therapy management (MTM) program and calculate consequent cost 
savings associated with improved clinical outcomes. METHODS: A total of 700 
employees from 2 employer groups participate in a pharmacist provided MTM 
program. A team of clinicians and researchers classiﬁed and created codes for speciﬁc 
pharmacist interventions, resultant physician and/or patient responses, and consequent 
outcomes. Data was extracted from patient charts and entered into Microsoft Excel. 
Costs associated with each decision outcome were calculated from claims data. A 
one-year decision-analytic model was constructed using TreeAge Pro Suite 2008 to 
identify the cost savings per intervention. RESULTS: A total of 218 interventions were 
made by the pharmacists. The most frequently used interventions were “explained and 
advised the use of pattern management” (N = 95, 43.4%) and “alerted the physician 
of an abnormal A1c level” (N = 64, 29.2%). Cost savings resulting from diabetic 
interventions for ER visits ($71.00 – $337 PPPY), inpatient hospitalization ($460.00 
– $2360.00 PPPY), and total costs ($26.00 – $274.00 PPPY). All but one intervention 
resulted in a loss of cost savings for ofﬁce visits, indicating that patients visited spe-
cialty physicians more often after beginning the program. The total cost savings for 
these interventions were $165.00 PPPY and $145.00 PPPY, respectively. CONCLU-
SIONS: This decision-analytic model can be used as a rubric for providers seeking the 
most effective interventions to utilize for MTM programs, thereby reducing trial-and-
error and diminishing health care costs. The model illustrates the potential return on 
investment the employer realized as a result of sponsoring employee participation in 
this program.
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IMPROVED PATIENT OUTCOMES RESULTING FROM PHYSICIANS’ 
THERAPY DECISIONS BASED ON PHARMACISTS’ RECOMMENDATIONS
Pinto S, Blazejewski L, Holl S
University of Toledo, Toledo, OH, USA
OBJECTIVES: Literature suggests that while pharmacists may be viewed as the most 
trusted health care professionals by patients, other health care professionals may 
often fail to trust them with making decisions regarding drug therapy regimens. 
Limited information is available regarding physicians’ therapy decisions based on 
pharmacist’s recommendations and the resulting patient clinical outcomes. This study 
aimed at ﬁnding if physicians’ therapy decisions based on pharmacist’s recommenda-
tions lead to optimal patient outcomes. METHODS: Approximately 700 employees 
from 2 employer groups have participated in an employer-supported pharmacist 
provided disease state management program. The program is provided at seven 
independent pharmacies across Northwest Ohio. A team of clinical pharmacists and 
researchers classiﬁed and created codes for speciﬁc pharmacist-provided interventions, 
resultant physician and/or patient responses, and consequent outcomes. Data was 
extracted from patient charts and entered into Microsoft Excel. Frequencies and 
percentages of pharmacists’ interventions, physicians’ responses and outcomes were 
calculated using SPSS ver. 17.0. A decision tree was created using TreeAge Pro Suite 
2008 to map interventions to responses to improved/unimproved outcomes. 
RESULTS: A total of 446 pharmacist interventions with corresponding physician 
responses and patient outcomes were made. The most frequent interventions involved 
drug therapy (N = 138, 31%) and formulary management (N = 105, 23.5%). The 
most frequent responses by physicians were “physician acknowledged recommenda-
tion, monitoring added” (N = 58, 13%) and “physician added a medication” (N = 
51, 11.4%). Physicians responded favorably to the pharmacists’ interventions 54.1% 
of the time. When physicians responded favorably, an improvement was seen in 
91.2% of patient outcomes compared to only 64% when physicians declined or did 
not respond to pharmacists’ interventions. CONCLUSIONS: Positive health out-
comes result from therapy decisions made by physicians following pharmacists’ 
recommendations. In an effort to save costs and improve care, pharmacist-physician 
collaboration is essential.
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RETROSPECTIVE ANALYSIS FOR DIABETES ACTION AND REPORTING 
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OBJECTIVES: To evaluate selected Healthcare Effectiveness Data and Information 
Set (HEDIS) comprehensive diabetes care measures in the i3 Innovus database by using 
the Retrospective Analysis for Diabetes Action and Reporting (RADAR) tool. 
METHODS: i3 Innovus data assets including medical and pharmacy claims from May 
2006 to May 2008 were used in the RADAR tool to assess the yearly rate of glyco-
sylated hemoglobin (HbA1c) testing and low-density lipoprotein-cholesterol (LDL-C) 
screening. Other HEDIS comprehensive diabetes care–related measures reported by 
the RADAR tool included the rate of patients with (a) hypertension; (b) nephropathy; 
and (c) retinopathy. Variables such as demographic, clinical, pharmacy, and medical 
utilization patterns along with medication adherence were also reported. RESULTS: 
A total of 287,195 patients with diabetes were identiﬁed, with 92% of the patients 
identiﬁed as having type 2 diabetes. Mean age of the patients was 53 years, and 52% 
were male. Over 70% of the patients with diabetes had cardiovascular risk factors 
such as hypertension; 4%, 13%, and 11% of the diabetes population had nephropa-
thy, neuropathy, and retinopathy, respectively. Sixty-seven percent of the diabetes 
patients received HbA1c testing, while 71% of the patients received LDL-C screening 
within one year. Testing within one year was less than the national HEDIS Medicaid 
25th percentile level (74.4%) for HbA1c and greater for LDL-C screening (66.9%). 
The RADAR tool effectively evaluated the selected HEDIS comprehensive diabetes 
care measures in the i3 Innovus database. CONCLUSIONS: In this population, LDL-C 
screenings within one year for diabetes patients were above the national HEDIS low-
performance level, while HbA1c testing within one year for diabetes patients was 
below the low-performance level, utilizing the RADAR tool for analyses. These ﬁnd-
ings indicate an opportunity for improvement.
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OBJECTIVES: Type 2 diabetes mellitus is serious condition associated of chronic 
complications whose economic impact on both patients and society is constantly 
increasing. Diabetics are the 4st in the drug spending in Slovakia. Our objectives was 
to explore drug costs for diabetes and besides the costs to explore also drug consump-
tion and number treated patients with antidiabetics. METHODS: The data on drugs 
consumption were from national databases IMS Health and Pharmadata Ltd. with 
293.935 diabetic patients cohort data in 4 years. To look into the impact of the drug 
policies in the Slovak Republic in 2006–2009. We calculated the impact of several 
regulatory measures on the size of the market and health insurance expenditure. 
Among the evaluated measures were: a) Lowering the VAT for drugs from 19% to 
10%, effective from 2007 b) ﬂat price cut in 2007 (-6.6%) and in 2008 (-7.4%) c) 
introduction of degressive mark-up for wholesalers and for pharmacies d) ﬁrst and 
second rounds of the international reference pricing for all drugs in 2009. RESULTS: 
The total antidiabetics volume (oral antidiabetics + insulin) of the Slovak market in 
2009 was °38.9 mil in manufacturers´ prices. 5% of the population with type 2 dia-
betes accounted for 8% of the total health care expenditure in Slovakia. In 2006 to 
2009 number of treated patients with antidiabetics increased by 11%. In 2006 to 2009 
7 new antidiabetics (molecules) entered the market. The regression results (40.0 vs 
°38.9 mil) suggested a positive relationship between the reimbursement price and 
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probability of prescribing brand name antidiabetics. CONCLUSIONS: DM diagnosis 
implies a relevant economic impact, has a high cost to society. The price regulation 
in 2006 to 2009 was able to generate the proﬁt and decresing the share of pharma 
expenditure in total health expenditure while increasing access new to drugs, and 
keeping the copayments low.
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OLDER PATIENTS WITH NEWLY DIAGNOSED TYPE 2 DIABETES 
(T2DM) EXPERIENCE MORE DELAYED TREATMENT WITH  
ORAL ANTIHYPERGLYCEMIC AGENTS COMPARED WITH  
YOUNGER PATIENTS
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OBJECTIVES: This study compared older (≥ 65 yrs) and younger patients with newly 
diagnosed T2DM, and evaluated factors associated with oral antihyperglycemic agent 
(OAHA) initiation. METHODS: This retrospective cohort study used U.S. General 
Electric (GE) Centricity electronic medical record database. Patients aged ≥30 yrs with 
newly-diagnosed T2DM (January-2003 to December-2005) were included. There was 
no diabetes diagnosis or treatment within 2 years prior to the ﬁrst recorded T2DM 
diagnosis. Medical records 1 year prior to (baseline) and 2 years after (follow-up) 
diagnosis were extracted. OAHA initiation was estimated based on the ﬁrst OAHA 
prescription during follow-up. Multivariable Cox proportional hazards regression 
model was ﬁtted. Untreated patients were censored at complete 2 years follow-up. 
RESULTS: Among 10,760 newly diagnosed T2DM patients, 55% were female. Mean 
age at T2DM diagnosis was 61.3( ± 12.5), with 4,617 (43%) ≥65 yrs. At baseline, 
older relative to younger patients had lower HbA1c (6.7% vs. 7.2%, with only 38% 
vs. 32% attaining HbA1c < 7% goal), lower fasting blood glucose (117.9 vs. 132.8 mg/
dL) and lower BMI (30.6 vs. 35.2), higher rates of acute myocardial infarction (MI) 
(2.1% vs. 0.9%), heart failure (5.1% vs. 1.8%), stroke (3.1% vs. 0.8%), and renal 
disease (17.5% vs. 6.2%), and more co-medications (all p-values < 0.05). Within 2 
years after T2DM diagnosis, 56% older and 40.5% younger patients (P < 0.001) had 
not received OAHA. Older patients were less likely to be treated than younger patients 
(adjusted hazard ratio 0.84, p < 0.001). Additionally, patients with baseline MI 
or renal disease were less likely to be treated (p < 0.05). Higher BMI or HbA1c at 
baseline, and heart failure, initiating antihypertensive or lipid lowering drugs after 
T2DM diagnosis were factors associated with increased likelihood of OAHA treat-
ment (p < 0.05). CONCLUSIONS: Older patients with newly diagnosed T2DM had 
milder hyperglycemia but more comorbidities, and experienced more delayed OAHA 
therapy than younger patients.
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EVALUATION OF SITAGLIPTIN DOSING AMONG RENAL IMPAIRED 
TYPE 2 DIABETES MELLITUS PATIENTS
Krishnarajah G, Dezii C, Tran M, Balar BA
Bristol Myers Squibb, Plainsboro, NJ, USA
OBJECTIVES: To evaluate the dosing of sitagliptin for type 2 diabetes mellitus 
(T2DM) patients with renal impairment. METHODS: This was a retrospective cross-
sectional analysis using the General Electric Electronic Medical Records. The study 
population (N = 1539) was patients with T2DM and renal impairment (deﬁned 
using ICD-9-CM codes) who were prescribed sitagliptin between April 1, 2006 and 
June 30, 2008. Based on the label, 100mg of sitagliptin is the recommended dose 
for patients with normal or mild renal impairment (CrCl≥50), 50mg for patients 
with moderate renal impairment (50 > CrCl≥30), and 25mg for severe or end-stage 
renal disease (ESRD)(30 > CrCl). Baseline severity of renal impairment was deter-
mined using calculated GFR values using the 4-point Modiﬁcation of Dosing in 
Renal Disease (MDRD) formula. Patients with GFR level ≥60 were considered normal 
to mild cases, 30 to < 60 were moderate cases, 15 to <30 were severe cases, and 
<15 or patients on dialysis had ESRD. Univariate analysis was done on age, gender, 
race, US region, payment source, comorbidities and Charlson-comorbidity index 
to identify factors that may be associated with inappropriate dosing. RESULTS: 
Of the 1,539 renally impaired patients with T2DM who received sitagliptin, 
804(52%) had moderate renal impairment and 158(11%) had severe renal impair-
ment or ESRD. Two-thirds of all moderate to severe and ESRD renally impaired 
patients had initial sitagliptin prescriptions that were higher-than-recommended 
doses. At 12-month follow-up, 87% of patients, whose initial prescription was for 
a higher-than-recommended-dose of sitagliptin, continued to be on the inappropriate 
higher dose. Univariate analysis showed there were no signiﬁcant differences 
in dosing by age, gender, race, US region, insurance type or comorbidities. 
CONCLUSIONS: Indiscriminant of patient characteristics, 2/3’s of the population 
of sitagliptin users recommended a lower dose due to renal impairment, were found 
to be inappropriately dosed higher-than-recommended. This inappropriate dosing 
was not corrected during a year-long follow-up.
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POTENTIALLY PREVENTABLE HOSPITALIZATIONS FOR DIABETES 
COMPLICATIONS, CARE ORGANIZATION AND CONTINUITY OF CARE
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OBJECTIVES: Understanding affects of care organization and continuity of care on 
potentially preventable hospitalizations for diabetes complications (DC) is important 
for policy development and outcomes management. We determined DC rates among 
Medicaid beneﬁciaries and assessed associations between care organization and DC. 
METHODS: A retrospective cohort analysis of Indiana Medicaid claims, enrollment, 
and encounter data was conducted. Sample inclusion criteria were ≥18 y/o, diabetes 
based on ICD-9 codes or NDC codes for diabetes speciﬁc medications, and continuous 
eligibility in 2008. Exclusion criteria were a nursing home stay or no claims in 2008. 
DCs were identiﬁed based on AHRQ diabetes prevention quality indicators for short-
term complications, uncontrolled diabetes, long-term complications and amputations. 
Each individual was placed in one of four groups based on whether continuously 
enrolled in Fee for Service (FFS), Care Management (CM), Managed care (MC), or 
whether switches between subprograms occurred in 2008. Persons enrolled in CM 
entered through disability determination, while other groups had no known disability 
indication. Logistic regression assessed association between Medicaid subprogram and 
DC adjusting for age, gender, ethnicity, marital status, diabetes type, mental illness, 
hypertension, coronary artery disease, foot speciﬁc conditions and Charlson comor-
bidity index. RESULTS: A sample of 47,443 persons, with mean age of 53 years, 68% 
female and, 77% white was identiﬁed. Overall, 1,514 hospitalizations for DC (95% 
C.I., 1439 - 1592) with a rate of 31.9 per 1000 individuals with diabetes was found. 
Although no signiﬁcant difference was seen between CM or MC as compared to FFS, 
DCs were more likely in individuals who switched subprograms than those in FFS 
(Odds ratio = 1.6, 95% C.I.: = 1.4 – 1.9, p≤0.001). CONCLUSIONS: Transitions 
between Medicaid subprograms was associated with greater likelihood of diabetes 
complication hospitalization. CM may reduce adverse outcomes for those persons 
with medical disability. Continuity of care may be essential.
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BACKGROUND AND OBJECTIVES: Diabetes is a chronic, potentially disabling 
and often fatal disease. The International Diabetes Federation estimates that more 
than 245 million people around the world are living with diabetes. Around 3.2 
million deaths are attributable to complication of diabetes every year; six deaths 
every minute. Pakistan is in the top ten countries in the number of sufferers from 
diabetes. This disease requires continuing proper medical care and patient self-
management education to prevent complications Current study aims to observe the 
current standard in the management of diabetic at a private tertiary care hospital 
in Karachi, Pakistan. METHODS: A retrospective health record review was done 
at a private tertiary care hospital at Karachi, Pakistan. Health records for all the 
persons with diabetes, who visited general physician or family physician during the 
months of April and May 2007, were included in this study. Two indicators includ-
ing foot examination and advice for HbA1C diagnostic test for this cross sectional 
survey were identiﬁed. Data were analyzed using descriptive statistics. RESULTS: 
Total 350 health records were reviewed and of these, 40% were males and 60 
females. Majority of the diabetics (80%) were over the age of 50 years. We found 
that only 40% of the patients were physically checked for foot examination and 
advised for HbA1C lab investigation by their general physician or family physician. 
About 44% were not either checked for foot examination or advised for HbA1C. 
CONCLUSIONS: Diabetes is a devastating chronic disease and can result in death 
very early if not managed properly. Current study suggest that adherence to the 
current screening guidelines was inadequate in this practice setting. Adherence to 
current diabetes management guidelines and diabetes care quality improvement initia-
tives can result in signiﬁcant improvements in the provision and documentation of 
diabetes care.
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TREATMENT OF TYPE 2 DIABETES VS. CLINICAL GUIDELINES
Tempas K, Skovira M, Kohli P, Wu Y
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OBJECTIVES: Determined how treatment of type 2 diabetes with drug therapy 
mirrors the accepted published clinical guidelines (for example those provided by the 
American Association of Clinical Endocrinologists). This included both initial drug 
therapy as well as therapies added over time. METHODS: Catalina Health Resource 
receives data from a nationally representative sample of pharmacy chains, representing 
approximately 40% of all national retail prescription volume, and comprised of over 
130 million unique patients. Data are captured daily from the pharmacies, are fully 
HIPAA compliant, longitudinal, and not projected. Patient cohort included all patients 
who initiated type 2 diabetes treatment January-March 2006. Look-back period was 
180 days and look-forward period was through December 2008. RESULTS: Patient 
cohort consisted of 77,302 new type 2 diabetes patients. Metformin is the recom-
mended initial therapy, but only 61% of patients were prescribed it as their initial 
therapy. The remaining patients began on a sulfonylurea (23%) or a thiazolidinedione 
(15%). 62% of patients who started on metformin did not add other drugs during 
the study, as compared to 48% of patients who started therapy on an SFU and 43% 
of patients who started therapy on a TZD. 1% of patients who started on metformin 
added/switched to basal insulin as their second drug, mean time to add/switch was 
547 days. 3% of patients who started on an SFU added/switched to basal insulin as 
their second drug, mean time to switch was 541 days. CONCLUSIONS: Nearly 40% 
of type 2 diabetes patients did not initiate therapy in line with published guidelines. 
Patients who initiated therapy on metformin had the highest rate of remaining on 
monotherapy. Patients who initiated therapy with metformin also had a lower rate of 
switching to/adding basal insulin as their second drug than patients who initiated 
therapy on an SFU.
